RE:RE:RE:RE:EU approves first I/O combinationAs I have repeated stated ONCY's pelareorep enhances the effectiveness of immune checkpoint inhibitors and now that Roche, Pfizer and Merck are developing subcutaneous formulations, the likely strategy is to combine pelareorep with one or all of the respective checkpoint inhibitors, (through subsequent out-licensing of pelareorep after the acquisition of ONCY), in both IV as well as with these newer SC delivery systems, which could be the proposition for multiple continuing Phase 3 confirmatory studies involving pelareorep in combination with Roche's Pfizer's, Incyte's, and/or Merck's checkpoint inhibitors.